HSD1 Antibody

Introduction to HSD1 Antibody

HSD1 (11-beta-hydroxysteroid dehydrogenase type 1) antibodies are specialized immunological tools designed to detect and study the 11β-HSD1 enzyme, which regulates glucocorticoid metabolism by converting inactive cortisone to active cortisol . These antibodies are critical for investigating the enzyme's role in metabolic disorders, inflammation, and tissue-specific glucocorticoid signaling . Commercial HSD1 antibodies, such as AF3397 (R&D Systems) and ASA-B0900 (Novatein Biosciences), are validated for applications including Western blotting, immunohistochemistry, and immunocytochemistry across human, mouse, and rat models .

Molecular Structure and Function of 11β-HSD1

Key characteristics of 11β-HSD1:

• Molecular weight: ~35–40 kDa (glycosylated form) .

• Enzymatic activity: Bidirectional catalysis of cortisol-cortisone interconversion, with a predominant reductase role in vivo .

• Tissue distribution: Highly expressed in liver, adipose tissue, and neutrophils; dynamically regulated during inflammation .

• Isoforms: Distinct from 11β-HSD2, which exclusively catalyzes cortisol inactivation .

Research Applications of HSD1 Antibodies

HSD1 antibodies enable:

• Localization studies: Identifying 11β-HSD1 expression in neutrophils during thioglycollate-induced peritonitis and epidermal keratinocytes in atopic dermatitis .

• Functional assays: Assessing enzyme activity changes under inflammatory conditions (e.g., LPS stimulation) .

• Therapeutic development: Evaluating inhibitors like BVT.2733 for metabolic and inflammatory diseases .

Role in Inflammation

• Neutrophils recruited during sterile peritonitis exhibit high 11β-HSD1 activity, which restrains excessive inflammation by amplifying local glucocorticoid signaling .

• Genetic or pharmacological inhibition of 11β-HSD1 increases pro-inflammatory cytokine production (IL-6, IL-1β) in macrophages and keratinocytes .

Metabolic and Dermatological Implications

• In atopic dermatitis (AD), 11β-HSD1 knockdown in keratinocytes elevates thymic stromal lymphopoietin (TSLP), exacerbating skin inflammation .

• Whole-body 11β-HSD1 knockout mice show aggravated AD symptoms, highlighting its protective role in modulating cutaneous glucocorticoid activity .

Tumor Microenvironment

• 11β-HSD1 inhibition does not directly affect tumor angiogenesis but may influence cancer progression through inflammation and fibrosis modulation .

Implications for Therapeutic Development

Selective 11β-HSD1 inhibitors (e.g., BVT.2733) show promise in:

• Attenuating inflammation: Reducing IL-6 and TNF-α in LPS-stimulated macrophages via NF-κB/MAPK pathway suppression .

• Metabolic disorders: Modulating glucocorticoid excess in obesity and insulin resistance .

• Dermatology: Mitigating AD progression by maintaining epidermal glucocorticoid homeostasis .